Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 145Carcinoma, Intraductal, Noninfiltrating 12Breast Carcinoma In Situ 10Neoplasm Metastasis 9Breast Neoplasms, Male 9Neoplasms 5Ovarian Neoplasms 4Prostatic Neoplasms 3Inflammatory Breast Neoplasms 3Gliosarcoma 3Glioma 3Glioblastoma 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Central Nervous System Neoplasms 3Carcinoma, Ductal, Breast 3Brain Neoplasms 3Urinary Bladder Neoplasms 2Sarcoma 2Oligodendroglioma 2Multiple Endocrine Neoplasia Type 1 2Liver Neoplasms 2Hot Flashes 2Glioma, Subependymal 2Fibroadenoma 2Ependymoma 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Astrocytoma 2Thyroid Neoplasms 1

Interventions

Nivolumab 13Surveys and Questionnaires 6Ipilimumab 6linrodostat 5Standard of Care 5Paclitaxel 5Bevacizumab 5Sirolimus 4Pemetrexed 4Interviews as Topic 4Gemcitabine 4Docetaxel 4ARRY-334543 4temsirolimus 3relatlimab 3Erlotinib Hydrochloride 3Cetuximab 3Carboplatin 3regorafenib 2anlotinib 2abemaciclib 2Vorinostat 2Trastuzumab 2Sorafenib 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Dasatinib 2Cyclophosphamide 2vorolanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Cancer × Tamoxifen × Clear all
NCT01393990 2020-03-24

A Study of LY2228820 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
89 enrolled 30 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡